Department of Neuropsychiatry, Showa University School of Medicine, Tokyo, Japan.
Department of Psychiatry and Institute for Clinical Research, National Hospital Organization Kure Medical Center, Kure, Japan.
Neuropsychiatr Dis Treat. 2013;9:1867-72. doi: 10.2147/NDT.S53386. Epub 2013 Dec 6.
Recently, the sigma-1 receptor has been shown to play a significant role in the neural transmission of mood by regulating N-methyl-D-aspartate receptors. Additionally, the sigma-1 receptor has been reported to influence cognitive functions including learning and memory. In this study, we measured plasma sigma-1 receptor concentrations before and after antidepressant treatment in patients with late-life major depressive disorder (MDD) and explored whether changes in depressive status are related to sigma-1 receptor concentrations.
The study participants were 12 subjects with late-life MDD diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. All of the participants were over 60 years old. Immediately prior to and 8 weeks after the start of treatment, sigma-1 receptor concentration and mental status, including depressive symptoms (Hamilton Depression Rating Scale; HAM-D), were measured. Treatment for depression was performed according to a developed algorithm based on the choice of treatments. We examined the association between changes in sigma-1 receptor concentration and HAM-D scores during antidepressant treatment. For the measurement of plasma sigma-1 receptor concentration, blood plasma samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Western blots were performed using a specific antibody that acts against the sigma-1 receptor, and the net densities of each band were quantified.
All participants showed improvement in depressive symptoms, which was indicated by a significant decrease in the HAM-D scores. The mean plasma sigma-1 receptor concentration also increased significantly following antidepressant treatment. However, no significant correlations were found between changes in plasma sigma-1 receptor concentration and changes in HAM-D scores.
In this preliminary study, we demonstrated that the sigma-1 receptor concentration in plasma increases following antidepressant treatment in patients with late-life MDD. Further studies are warranted to confirm this finding with a larger number of patients.
最近,西格玛-1 受体通过调节 N-甲基-D-天冬氨酸受体,在情绪的神经传递中发挥着重要作用。此外,西格玛-1 受体已被报道影响认知功能,包括学习和记忆。在这项研究中,我们测量了老年期重度抑郁症(MDD)患者抗抑郁治疗前后的血浆西格玛-1 受体浓度,并探讨了抑郁状态的变化是否与西格玛-1 受体浓度有关。
研究参与者为 12 名根据精神障碍诊断与统计手册,第四版标准诊断的老年期 MDD 患者。所有参与者均超过 60 岁。在开始治疗前和治疗 8 周后,立即测量西格玛-1 受体浓度和精神状态,包括抑郁症状(汉密尔顿抑郁评定量表;HAM-D)。根据基于治疗选择的开发算法进行抗抑郁治疗。我们检查了抗抑郁治疗期间西格玛-1 受体浓度变化与 HAM-D 评分之间的关系。为了测量血浆西格玛-1 受体浓度,通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳分离血血浆样本。使用针对西格玛-1 受体的特异性抗体进行 Western blot,并且对每个条带的净密度进行定量。
所有参与者的抑郁症状均有改善,HAM-D 评分显著降低。抗抑郁治疗后,平均血浆西格玛-1 受体浓度也显著增加。然而,在血浆西格玛-1 受体浓度变化与 HAM-D 评分变化之间未发现显著相关性。
在这项初步研究中,我们证明了老年期 MDD 患者抗抑郁治疗后血浆西格玛-1 受体浓度增加。需要进一步的研究来确认这一发现,纳入更多的患者。